A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of SHR-2173 in Patients With Systemic Lupus Erythematosus

Inclusion criteria

• Age 18-65 years, regardless of gender;
• Weight ≥45.0 kg at screening;
• Confirmed SLE diagnosis for ≥12 weeks at screening.

Exclusion criteria

• Pregnant or breastfeeding women, or those with a positive human chorionic gonadotropin (HCG) test.
• History of alcohol abuse or illegal drug use within one year prior to screening.
• Blood donation ≥450 mL within 8 weeks prior to screening or plans to donate blood during the study.
• Current active infection or a history of active tuberculosis
• Other inflammatory or autoimmune diseases beyond SLE and LN that may interfere with the interpretation of trial results or clinical assessment.